Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Reforming the Payment System for Medical Oncology

Reforming the Payment System for Medical Oncology Opinion Reforming the Payment System VIEWPOINT for Medical Oncology Infusion of chemotherapy has long been a profit cen- cess problems if reimbursement levels continue to Peter B. Bach, MD, MAPP ter for medical oncologists. Under the current system, decline. However, Medicare appears to have limited op- Memorial oncologists purchase cancer drugs at one price, then bill tions, and it is difficult to gauge how Congress will act Sloan-Kettering Cancer insurers at a higher price after they administer the drugs. in these restrained fiscal times. Center, New York, New However, the profits available to oncologists from this The current perceived crisis should trigger a more York. practicehavebeenunderseriouspressurefromthephar- comprehensive consideration of how oncology medi- maceutical industry and insurers. Pharmaceutical com- cations should be financed, and what role, if any, prof- panies have rapidly increased drug prices while insur- its linked to drug prescribing should play. Three cancer ers,includingtheMedicareprogram,havesystematically payment reform approaches have been proposed that decreased the reimbursement they provide above the address the link between cancer drug prices and physi- cost of the drug. Even though rising drug prices mean, cian profits. in general, larger absolute profits to oncologists when Episode-based payment creates specific incen- they administer more expensive drugs http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Reforming the Payment System for Medical Oncology

JAMA , Volume 310 (3) – Jul 17, 2013

Loading next page...
 
/lp/american-medical-association/reforming-the-payment-system-for-medical-oncology-QeLEumTc0M
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2013.8127
pmid
23817729
Publisher site
See Article on Publisher Site

Abstract

Opinion Reforming the Payment System VIEWPOINT for Medical Oncology Infusion of chemotherapy has long been a profit cen- cess problems if reimbursement levels continue to Peter B. Bach, MD, MAPP ter for medical oncologists. Under the current system, decline. However, Medicare appears to have limited op- Memorial oncologists purchase cancer drugs at one price, then bill tions, and it is difficult to gauge how Congress will act Sloan-Kettering Cancer insurers at a higher price after they administer the drugs. in these restrained fiscal times. Center, New York, New However, the profits available to oncologists from this The current perceived crisis should trigger a more York. practicehavebeenunderseriouspressurefromthephar- comprehensive consideration of how oncology medi- maceutical industry and insurers. Pharmaceutical com- cations should be financed, and what role, if any, prof- panies have rapidly increased drug prices while insur- its linked to drug prescribing should play. Three cancer ers,includingtheMedicareprogram,havesystematically payment reform approaches have been proposed that decreased the reimbursement they provide above the address the link between cancer drug prices and physi- cost of the drug. Even though rising drug prices mean, cian profits. in general, larger absolute profits to oncologists when Episode-based payment creates specific incen- they administer more expensive drugs

Journal

JAMAAmerican Medical Association

Published: Jul 17, 2013

References